Emily Kobayashi (Gavi) outlined the transition to the Gavi 6.0 strategy during the 2025 CHIC Symposium. The intervention detailed the consolidation of multiple funding streams into a single holistic grant model and a unified cash envelope to enhance transparency and country sovereignty. Key policy shifts include the introduction of country vaccine budgets with financing ceilings […]
Topic: 5. Financing & Gavi
Resource Mobilization and Financial Sustainability: Financial sustainability for HPV vaccination – Zimbabwe
In Zimbabwe, HPV vaccination was introduced nationally in 2018 targeting Grade 5 girls, with initial financing largely provided by Gavi and government co-financing covering procurement and delivery. To sustain the programme amid competing health priorities and fiscal constraints, Zimbabwe has pursued a multi-pronged financing and integration strategy. Key steps include embedding a dedicated HPV budget […]
Resource Mobilization and Financial Sustainability: Financial sustainability for HPV vaccination – Malawi
In Malawi, financial sustainability for HPV vaccination is pursued against a backdrop of significant programmatic complexity and recurrent health emergencies, including COVID-19, polio, cholera outbreaks, and cyclone-related displacement. Cervical cancer is the leading cause of cancer death among women aged 15–49 in Malawi, with an age-standardised incidence of 67.9 per 100,000 women per year and […]
Resource Mobilization and Financial Sustainability: Common challenges in preparing for the Gavi transition – Cote d’Ivoire
In Côte d’Ivoire, the transition away from Gavi financing represents one of the most significant programmatic and financial challenges facing the national immunization programme. Having benefited from Gavi support since 2001, the country entered the accelerated transition phase in late 2022, with a target of full self-financing by 2030. This transition implies a more than […]
Resource Mobilization and Financial Sustainability: Common challenges in preparing for the Gavi transition – Kenya
In Kenya, sustaining HPV vaccination within a life-course immunization framework has become an increasingly urgent policy priority as the country navigates its transition away from Gavi support. Kenya has partnered with Gavi since 2001 — receiving over US$940 million in cumulative support — and introduced HPV vaccination into the routine schedule in 2019; it entered […]
Resource Mobilization and Financial Sustainability: After Gavi: South Africa’s experience crafting a sustainable HPV vaccination program
In South Africa, HPV vaccination has been fully domestically financed since 2014 through a National Treasury conditional grant — without Gavi support — with provincial allocations rising from R49 million in 2024/25 to a projected R72 million in 2026/27. The programme transitioned to a single-dose schedule from 2023 and expanded to private and independent schools […]
HPV vaccine product landscape
Global HPV vaccine coverage stood at 28% of the female target population in 2024 despite 80% of WHO member states having introduced the vaccine, with the coverage gap driven by the delayed introduction of large-population countries including India, China, and Pakistan. The shift to single-dose schedules has fundamentally reshaped global demand dynamics: in 2024, a […]
Panel Discussion on funding and financial sustainability
Global partners converged on a shared concern: development assistance for health is projected to fall by nearly 50% between 2021 and 2030, placing acute pressure on African countries where external funding covers more than a third — and in some cases more than half — of health expenditures. Gavi reaffirmed its commitment to HPV vaccination, […]
HPV vaccine cost and procurement: Q&A Session
The session’s discussion highlighted supply dynamics and market diversification for HPV vaccines, with UNICEF confirming five WHO-prequalified products currently available and several others in the pipeline, including a quadrivalent vaccine from SII. Participants raised questions on whether increased suppliers could reduce prices and how demand fluctuations after multi-age cohorts might affect costs. Indonesia and Lao […]
Gavi Investments
The Gavi session outlined its 2022 “must‑win” priority to scale up HPV vaccination, aiming to immunize 86 million girls by 2025. It detailed support for both Gavi‑eligible and middle‑income countries, including vaccine grants, operational funding, health‑system strengthening, and pooled procurement mechanisms. The presentation highlighted rapid progress post‑COVID, new multi‑age cohort campaigns, and upcoming introductions in […]